A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
Reason given: After careful review of Taiho's ongoing portfolio and data obtained so far in the context of broader landscape of clinical development in NSCLC HER2mut, Sponsor has made a strategic decision to terminate this study and not based on safety concerns.
Key facts
- Where
- Houston and Nashville, United StatesSee the 2 sites
- Phase
- Phase 1
Where in United States
- University of Texas - MD Anderson Cancer CenterHouston, United StatesNo longer taking part
- Tennessee OncologyNashville, United StatesNo longer taking part
Trial details
- Who runs it
- Taiho Oncology, Inc.
- Trial code
- NCT04982926
- Record updated
- 14 October 2025
- Original description
This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid tumors who are not candidates for approved or available therapies.Read full original descriptionShow less
A Phase 1 Study of TAS2940 in Patients With Locally Advanced or Metastatic Solid Tumors With EGFR and / or HER2 Aberrations
This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid tumors who are not candidates for approved or available therapies.
Inclusion: Have histologically confirmed solid cancer that is locally advanced and metastatic and available standard treatment options have been exhausted; Have adequate organ function; ECOG PS 0-1; Dose Escalation:; Have measurable or non- measurable disease per RECIST criteria v1.1 or RANO; Any solid tumor with EGFR and / or HER2 aberration; Dose Expansion:; Have measurable disease per RECIST criteria v1.1 for solid tumor (excluding primary brain tumor) or RANO (for glioblastoma); Cohort A: Non-small cell lung cancer (NSCLC); Cohort B: HER2 positive breast cancer; Cohort C: Recurrent or refractory glioblastoma; Cohort D: Other solid tumors with EGFR or HER2 aberrations.
Exclusion: Have significant cardiovascular disorder; Have not recovered from prior cancer treatment; A serious illness or medical condition; Non-stable brain metastases.